4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Smoking Cessation by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 200 ongoing clinical trials involving Smoking Cessation
Of the 200 trials,84 trials are in Phase II
Furthermore, 43 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Smoking Cessation by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Smoking Cessation, a Central Nervous System indication. The largest number of ongoing clinical trials for Smoking Cessation is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions engaged in Smoking Cessation-related drug trials.

Smoking Cessation related clinical trials sponsors

University of Bern, University of Texas MD Anderson Cancer Center, Medical University of South Carolina, and Abramson Cancer Center are a few notable clinical trial sponsors involved in Smoking Cessation. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Smoking Cessation

Varenicline tartarate (Champix, Chantix), Nicotine (Nicoretteskin, Nicotrol, Nicorette, Nicorette TX, Nicorette Citrus), and Bupropion hydrochloride (Zyban, Zyntabac, Quomem) are key marketed drugs involving Smoking Cessation.

Varenicline tartarate (Champix, Chantix) is an anti-addiction class of drug. It functions via Neuronal Acetylcholine Receptor Subunit Alpha 4 Agonist, Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) Agonist mechanism of action. It is formulated as tablets and film-coated tablets for oral route of administration. It is indicated as an aid to smoking cessation treatment. It was under development for Alzheimer's disease and Friedreich Ataxia, spinocerebellar ataxia. Varenicline tartarate was first approved in 2006 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Pfizer Inc.

Nicotine (Nicoretteskin, Nicotrol, Nicorette, Nicorette TX, Nicorette Citrus) is a highly toxic alkaloid. It functions via Cholinergic Receptor Nicotinic Subunit Agonist mechanism of action. It is formulated in various forms such as solution, tablets, gum, spray, powder for the oral route, patch for transdermal, tablet, chewable tablet and sublingual, lozenge for buccal, spray, solution for nasal and inhalational, and aerosol spray for the buccal route of administration. Nicotine is indicated to relieve and/or prevent craving and nicotine withdrawal symptoms associated with tobacco dependence. Nicotine was first approved in 1978 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by GlaxoSmithKline LLC.